Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual fentanyl for breakthrough cancer pain
IRCT20131124015515N8Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fentanyl in breakthrough cancer pain (BTcP) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Pain intensity and Episode of pain. Started Jul 2019; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on IRCT20131124015515N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131124015515N8.